JNJ-4528 Remains Under Evaluation for Relapsed/Refractory Multiple Myeloma

Jesus Berdeja, MD, discusses the next steps for the chimeric antigen receptor T-cell therapy JNJ-4528 following the data from the phase 1b portion of the CARTITUDE-1 trial in patients with relapsed/refractory multiple myeloma.

Jesus Berdeja, MD, the director of Multiple Myeloma Research at Sarah Cannon Research Institute, discusses the next steps for the chimeric antigen receptor (CAR) T-cell therapy JNJ-4528 following the data from the phase 1b portion of the CARTITUDE-1 (NCT03548207) trial in patients with relapsed/refractory multiple myeloma.

The phase 2 portion of this study is now fully enrolled, says Berdeja. He is looking forward to combining data in this study with the findings from the phase 1b portion. The same dose from the initial study will be used in the phase 2. The purpose is to evaluate the durability of responses in this patient population, which have looked promising in the recently published data.

The FDA granted a Breakthrough Therapy Designation to JNJ-5428, and Berdeja hopes this will be a candidate for approval in the population of patients with relapsed/refractory multiple myeloma. Phase 2 and 3 studies are also underway looking at this CAR T product in earlier lines of therapy for patients with multiple myeloma, including the high-risk populations. The agent is even being evaluated as a frontline consolidation therapy in the myeloma landscape.

<< View more resources and information regarding multiple myeloma